Clonazepam

As a benzodiazepine central nervous system depressant, clonazepam enhances the inhibitory nerve conduction effect of γ-aminobutyric acid A receptors to reduce neuronal excitability, and is one of the core drugs for clinical control of epileptic seizures. In addition to the treatment of various types of epileptic absence seizures, infantile spasms, and myoclonic seizures, it can also be used for the intervention of mental disorders such as panic disorder and social anxiety disorder. The applicable population covers children and adult epilepsy patients, as well as patients with anxiety disorders who are required after clinical evaluation, making it a basic and commonly used drug in the neuropsychiatric field.

The current global market size of clonazepam is approximately USD 320 million. Driven by the rising prevalence of epilepsy and the increasing consultation rate of anxiety disorders, the compound annual growth rate remains at around 2.8%. As the core patents have long expired, the global market is dominated by generic drug supplies, with China and India being the main manufacturers and exporters of API. Affected by the control policies for psychotropic drugs, the domestic market has a high supply concentration, and the procurement price at public medical institutions is relatively stable.

The original developer of clonazepam is Roche, and the original brand name is "Rivotril/Clonazepam". Its core compound patent expired globally in 1979. The main dosage forms approved for the original product include tablets (0.5mg, 1mg, 2mg) and injections (1mg/1ml). The original tablets have been included in the *Catalogue of Reference Preparations of Chemical Drugs* of China, and are also listed in the FDA Reference Preparations Catalogue. According to the domestic API registration platform, more than 10 enterprises have obtained A-status registration numbers for clonazepam APIs so far, and the domestically approved clonazepam preparations on the market include two dosage forms: tablets and injections. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO provides a full set of clonazepam impurity reference standards. Relying on a multi-regulation compliant R&D system, all impurities meet the relevant quality requirements of the Chinese Pharmacopoeia and FDA. Most products are in regular stock, and spot orders submitted before 16:00 can be shipped on the same day, which can fully meet the reference standard use needs of the whole process including API R&D, quality research and preparation consistency evaluation.